About: Tackling COVID‐19 infection through complement‐targeted immunotherapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tackling COVID‐19 infection through complement‐targeted immunotherapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tackling COVID‐19 infection through complement‐targeted immunotherapy
Creator	Jodele, Sonata Joerg, Koehl Köhl, Jörg
topic	covid:433ecfd416a37d436a6f4ea2ca5490bbcbbc0e02#this
Source	Medline; PMC
abstract	The complement system is an ancient part of innate immunity sensing highly pathogenic coronaviruses by mannan‐binding lectin (MBL) resulting in lectin pathway activation and subsequent generation of the anaphylatoxins (AT) C3a and C5a as important effector molecules. Complement deposition on endothelial cells and high blood C5a serum levels have been reported in COVID‐19 patients with severe illness, suggesting vigorous complement activation leading to systemic thrombotic microangiopathy (TMA). Complement regulator gene variants prevalent in African Americans have been associated with a higher risk for severe TMA and multi‐organ injury. Strikingly, SARS‐CoV‐2‐infected African Americans suffer from high mortality. These findings allow us to apply our knowledge from other complement‐mediated diseases to COVID‐19 infection to better understand severe disease pathogenesis. Here we will discuss the multiple aspects of complement activation, regulation, crosstalk with other parts of the immune system and the options to target complement in COVID‐19 patients to halt disease progression and death.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1111/bph.15187
bibo:pmid	32643798
has license	no-cc
sha1sum (hex)	433ecfd416a37d436a6f4ea2ca5490bbcbbc0e02
schema:url	https://doi.org/10.1111/bph.15187
resource representing a document's title	Tackling COVID‐19 infection through complement‐targeted immunotherapy
has PubMed Central identifier	PMC7361469
has PubMed identifier	32643798
schema:publication	Br J Pharmacol
resource representing a document's body	covid:433ecfd416a37d436a6f4ea2ca5490bbcbbc0e02#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/433ecfd416a37d436a6f4ea2ca5490bbcbbc0e02
is schema:about of	named entity 'SARS-CoV-2' named entity 'Complement' named entity 'subsequent' named entity 'REGULATOR GENE' named entity 'endothelial cells' named entity 'high' named entity 'suffer' named entity 'severe' named entity 'ancient' named entity 'TMA' named entity 'complement activation' named entity 'effector molecules' named entity 'African Americans' named entity 'infection' named entity 'endothelial cells' named entity 'complement' named entity 'C5a' named entity 'complement activation' named entity 'C5a' named entity 'gene variants' named entity 'MBL' named entity 'effector molecules' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'anaphylatoxins' named entity 'C1q' named entity 'fatigue' named entity 'protein' named entity 'serum' named entity 'RNAseq' named entity 'ficolins' named entity 'C1 inhibitor' named entity 'IFN' named entity 'COVID-19' named entity 'complement' named entity 'SARS-CoV-2' named entity 'ARDS' named entity 'serine protease' named entity 'complement activation' named entity 'Eculizumab' named entity 'complement' named entity 'immunocompromised' named entity 'MERS-CoV' named entity 'COVID' named entity 'ARDS' named entity 'cell trafficking' named entity 'Complement' named entity 'phase II trials' named entity 'ALI' named entity 'pore-forming' named entity 'C1s' named entity 'pro-inflammatory' named entity 'protein' named entity 'sepsis' named entity 'COVID-19 disease' named entity 'C5aR1' named entity 'immunopathology' named entity 'TNF' named entity 'ALI' named entity 'phase II trial' named entity 'pneumonia' named entity 'C5b' named entity 'CRP' named entity 'SARS-CoV' named entity 'C5a' named entity 'clinical development' named entity 'seroconversion' named entity 'IFN' named entity 'SNP' named entity 'exon' named entity 'infection' named entity 'African Americans' named entity 'lung' named entity 'inflammatory disease' named entity 'adhesion' named entity 'African Americans' named entity 'inflammatory cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software